Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee debates expanding medical‑cannabis rules, including higher potency and inhalable options; action deferred
Summary
Senators, former lawmakers, patients and industry representatives debated a bill to rename the state program and expand authorized products, including raising THC caps and allowing inhalable delivery; the committee recessed and deferred action for further work.
The Regulated Industries Committee heard extended testimony and debate on Senate Bill 220, a multi‑part rewrite of the state’s low‑THC medical program that would retitle the program “medical cannabis,” raise potency caps for allowable products and broaden eligible conditions and delivery methods.
Key proposed changes in the bill presented to the committee include:
- Changing the program name from "low THC oil" to "medical cannabis." - Raising a potency cap for permitted oil products from 5% to 50% THC for certain delivery systems, citing…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
